AzTrials
AzTrials

Degenerative Lumbar SpondylolisthesisNCT06407063

Long-term Reoperations After Lumbar Spinal Stenosis Surgery

An observational study of Degenerative Lumbar Spondylolisthesis, run by University Hospital of North Norway at 1 site in Norway.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Severe and persisting pain and disability due to a degenerative narrowing of the spinal canal, lumbar spinal stenosis, can be operated with a simple surgical decompression. Sometimes, there is also a slippage of vertebra, degenerative spondylolisthesis. In such cases, instrumental stabilization (e.g. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Degenerative Lumbar Spondylolisthesis
What is being tested?
Micro-decompression alone and Decompression and instrumented fusion
Type of treatment
Surgery or procedure
How many people
794 participants
Where
1 siteNorway
Study dates
19 Sep 2007to 30 Apr 2026
How long will I take part?
8 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The population is defined by the NORspine registry and contains all patients in the register in the priode September 19 2007 to Desember 21 2015 that fulfil the eligibility criteria. The NORspine register cases in a specialiced health care setting from the Norwegian providers of lumbar spine surgery.

Who may be able to join

  • operated between September 2007 and December 2015 labeled in the registry with both 'Spinal stenosis' and 'Degenerative spondylolisthesis'
  • operated on with decompression with or without an additional fusion

Who cannot join

  • operated with an anterior approach
  • had a former operation at index Level
  • was labeled with a degenerative scoliosis
  • was operated in more than 2 Levels
  • was operated with non-instrumented fusion
  • operated with a standard laminectomy with removing of the posterior midline structures or operated without magnifying devices was excluded from the micro-decompression group

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Eirik Mikkelsen, MD contact

eirik.mikkelsen@unn.no

Tore Solberg, Prof contact

+47 91364531

Tore.Solberg@unn.no

Norway1 site, 1 recruiting
  • University hospital of North Norway

    Tromsø, 9038

    Tore Solberg, Prof, +47 91364531, Tore.Solberg@unn.no

    Erik Mikkelsen, MD, Erik.Mikkelsen@unn.no

    Recruiting

Other trials in Norway

About this study

Official title: Long-term Frequency of Reoperations After Micro-decompression Alone Versus Decompression and Instrumented Fusion in Patients With Lumbar Spinal Stenosis and Degenerative Spondylolisthesis

Severe and persisting pain and disability due to a degenerative narrowing of the spinal canal, lumbar spinal stenosis, can be operated with a simple surgical decompression. Sometimes, there is also a slippage of vertebra, degenerative spondylolisthesis. In such cases, instrumental stabilization (e.g. screws and rods) has been recommended. Even though additional fusion is more complex and riskier, and evidence in high-quality Scandinavian studies shows that it is unnecessary, decompression plus fusion is still the treatment of choice in the USA and most European countries. This reluctance to change clinical practice is mainly due to concerns about long-term results, especially higher reoperation rates among patients operated with decompression only. This register-based non-inferiority study aims to assess long-term reoperations among those treated with and without additional fusion surgery.

Read the detailed description

The use of fusion surgery in addition to decompression in the treatment of degenerative lumbar spondylolisthesis (DS) with spinal stenosis (LSS) is a long-standing controversy in spine surgery. The main goal of LSS surgery is to decompress the nerve roots. In the 1990s, two observational studies recommended that decompression with additional fusion should be the treatment of choice. Consequently, the practice shifted towards more complex fusion procedures. In 2016, Swedish and one American randomized controlled trials (RCTs), one Swedish and one American, reported conflicting data about reoperations. The study from the US showed a higher frequency of reoperations after decompression only compared to the decompression and fusion, while the Swedish study showed no difference. In 2020, Austevoll et. al. published a study from the Norwegian registry for spine surgery (NORspine) comparing relative effectiveness micro-decompression alone vs decompression and instrumented fusion (5). This study had a non-inferiority design, similar to the RCT published by the same author in 2021 (6). Both studies concluded that micro-decompression alone was non-inferior to decompression and instrumented fusion regarding clinical outcomes and reoperation rates. Despite an increasing number of studies showing no extra benefits from the more risky and complex additional fusion procedures, the surgical practice has changed little outside Scandinavia. This is probably due to the concerns about subsequent instability and higher long-term reoperation rates among those operated with decompression only.

This study is a long-term follow-up of the NORspine relative effectiveness study from 2020, comprising 794 patients having an index operation for LSS and DS between September 19th 2007 and December 21st 2015 (index study). The present study aims to assess long-term reoperations resulting from everyday clinical practice. The investigators alternative hypothesis is that micro-decompression alone is non-inferior to decompression plus instrumented fusion. The non-inferior margin is specified to correspond to a number needed to treat = 8 to avoid reoperation on one patient in the first 10 postoperative years, corresponding to a between-group difference of 12.5 percentage points (100/8 = 12.5).

The dataset will contain NORspine data at baseline, 3 months, one year and long-term follow-up performed at 7 to 15 years (NCT03469791). NORspine also provides dates of death for all deceased patients. The Norwegian Patient Registry (NPR) will serve as an external data source, providing data about all reoperations until August 31st 2023 and the baseline Charlson Comorbidity Index (CCI). NPR data will ensure follow-up of 8 to 16 years concerning reoperations. For these cases, a review the electronic health records to validate NPR data regarding classification of reoperation (level, indication, surgical technique, total number of reoperations, spinal cord stimulation, reoperations within 90 days after the index operation, participation in other studies).

In the index study propensity score matching (PSM) was performed to reduce the risk of selection bias due to case-mix. The same PSM will be used in the present study. matching. The following parameters were included in the calculation of the propensity score: Age; Gender; American Society of Anaesthesiologists (ASA) grade; Body Mass Index (BMI); Smoking, Oswestry Disability Index (ODI), Numeric Rating Scale for leg pain and back pain, Euroqol 5D (EQ-5D-3L), foraminal stenosis, degenerative disc disease, predominating back pain, number of levels operated on and neurological palsy. The propensity scores were derived from a logistic regression model and reflected a patient's theoretical baseline probability for being instrumentally fused. Using the '1:1 matching without replacement' method, pairs of fused and non-fused patients with a difference in propensity scores less than 0.2 in the logit of the standard deviation were formed. Statistical Package for the Social Sciences (SPSS) version 24 was used for propensity score matching. For comparison, complete case analyses will also be performed.

In this non-inferiority designed study, the primary outcome will be the occurrence of a reoperation, defined as new lumbar spine operation more than 90 days after the index operation until August 31st 2023 (range: from 8 to 16 years after the primary operation. The rate of reoperation within 90 days (n%) of will be reported separately, and will be classified as a complication to the index operation. Survival analysis will be used to detect whether the probability for reoperation during the first 10 years is more than 12.5 % higher (non-inferiority margin) in the micro-decompression group than in the decompression and instrumented fusion group or not. This is to be tested by deriving a 90 % confidence interval (CI) for the difference of the survival function (S(t)) at 10 years between the groups (S(t) in decompression and instrumented fusion group - S(t) in micro-decompression group) where t = 10 years. Thus, a lower limit of the CI above -0.125 will indicate that, in an everyday clinical practice setting, micro-decompression would be non-inferior to decompression and instrumented fusion regarding the risk of reoperation. In addition, the investigators will report survival functions and observed reoperation rates at multiple timepoints (2, 5 and 10 years), hazard ratio (HR) for reoperation (at 2, 5 and 10 years, as well as complications (including reoperations within 90 days). The indication for reoperation, surgical techniques and risk factors associated with reoperation will also be investigated.

For the power analysis conducted with PASS 2019, two assumptions were made. 1) Expected reoperation rate: Based on NORspine data, about 27.1 % of lumbar surgical procedures are performed on patients previously operated. Using this as a proxy for the expected probability of reoperation in the total cohort. 2) HR = 1.6 (decompression and instrumented fusion) approximates the event ratio between the groups. Applying these assumptions, choosing a type 1 error = 0.05 and power 0.8 gives sample size = 269 per group. The index study had a sample size of 285 in each PSM group. Since the present study will use national administrative registries and patient's health records, substantial loss to follow-up is not expected.

For statistical analyses SAS Enterprise Guide 8.3 will be used, including descriptive statistics, tests for data distribution, cross-tabulations with χ2 test, Student t-tests, and Mann-Whitney U tests. Reoperation survival, hazard and rates will be assessed by stratified log-rank test, cox regression modelling (time-dependent if the proportional hazard assumption is violated), Kaplan-Meier plots and multivariable regression analyses.

Being tested
Micro-decompression alone, Decompression and instrumented fusion
Keywords
Degenerative Spondylolisthesis, Treatment, Decompression alone, Instrumented fusion, Reoperations

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Micro-decompression aloneProcedure or surgery

    In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-preserving decompression without fusion

  • Decompression and instrumented fusionProcedure or surgery

    In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional cage

Study groups in NCT06407063
Study groupRoleWhat they receive
Patients treated for Degenerative SpondylolisthesisPatients operated for Degenerative Spondylolisthesis with Lumbar Spinal Stenosis
Receives: Procedure: Micro-decompression alone; Procedure: Decompression and instrumented fusion

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Estimated reoperations rate (n, %) at 10 years follow-up (Survival function (S(t), t=10 years) for first reoperation) by treatment group

    Survival function for a reoperation at 10 years. A new operation in the lumbosacral spine (excluding surgery for tumor and trauma) during follow up, occurring more than 90 days after index surgery is defined as reoperation.

    Measured: From date of index operation (2007-2015) until end of follow up August 31st 2023

Secondary outcomes (3)
  1. Hazard ratio(s) and survival functions for reoperation and reoperations rates by treatment group.

    Hazard ratio(s) and survival functions for reoperation and reoperations rates, reported at 2, 5 and 10 years follow-up. A new operation in the lumbosacral spine (excluding surgery for tumor and trauma) during follow up, occurring more than 90 days after index surgery is defined as reoperation.

    Measured: From date of index operation (2007-2015) until end of follow up August 31st 2023

  2. Rate of reoperations within 90 days after index surgery (n %) by treatment group.

    This is reported separately since early reoperations (within 90 days) are categorized as complications in the NORspine (n %)

    Measured: From date of index operation (2007-2015) until 90 days after index surgery

  3. Other complications (n %) by treatment group

    Complications (n %) related to index operation reported in NORspine. Surgeon and patient reported. e.g dural tear, postoperative haematoma, surgical site infection, thromboembolism (DVT, LE), pneumonia

    Measured: Reported at baseline and 3 months after the index operation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 May 2024
  2. Study start19 Sep 2007
  3. Primary completion11 Dec 2024
  4. Study completion30 Apr 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
794 participants (estimated)
Target duration
8 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT06407063
Sponsor's protocol ID
2813
Status last verified
Dec 2024
First submitted
6 May 2024
Last updated
17 Dec 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No sharing is planed due to the sensitive nature of the research data

Publications

  • Herkowitz HN, Kurz LT. Degenerative lumbar spondylolisthesis with spinal stenosis. A prospective study comparing decompression with decompression and intertransverse process arthrodesis. J Bone Joint Surg Am. 1991 Jul;73(6):802-8.

    PubMed 2071615
  • Bridwell KH, Sedgewick TA, O'Brien MF, Lenke LG, Baldus C. The role of fusion and instrumentation in the treatment of degenerative spondylolisthesis with spinal stenosis. J Spinal Disord. 1993 Dec;6(6):461-72. doi: 10.1097/00002517-199306060-00001.

    PubMed 8130395
  • Forsth P, Olafsson G, Carlsson T, Frost A, Borgstrom F, Fritzell P, Ohagen P, Michaelsson K, Sanden B. A Randomized, Controlled Trial of Fusion Surgery for Lumbar Spinal Stenosis. N Engl J Med. 2016 Apr 14;374(15):1413-23. doi: 10.1056/NEJMoa1513721.

    PubMed 27074066
  • Ghogawala Z, Dziura J, Butler WE, Dai F, Terrin N, Magge SN, Coumans JV, Harrington JF, Amin-Hanjani S, Schwartz JS, Sonntag VK, Barker FG 2nd, Benzel EC. Laminectomy plus Fusion versus Laminectomy Alone for Lumbar Spondylolisthesis. N Engl J Med. 2016 Apr 14;374(15):1424-34. doi: 10.1056/NEJMoa1508788.

    PubMed 27074067
  • Austevoll IM, Gjestad R, Solberg T, Storheim K, Brox JI, Hermansen E, Rekeland F, Indrekvam K, Hellum C. Comparative Effectiveness of Microdecompression Alone vs Decompression Plus Instrumented Fusion in Lumbar Degenerative Spondylolisthesis. JAMA Netw Open. 2020 Sep 1;3(9):e2015015. doi: 10.1001/jamanetworkopen.2020.15015.

    PubMed 32910195
  • Austevoll IM, Hermansen E, Fagerland MW, Storheim K, Brox JI, Solberg T, Rekeland F, Franssen E, Weber C, Brisby H, Grundnes O, Algaard KRH, Boker T, Banitalebi H, Indrekvam K, Hellum C; NORDSTEN-DS Investigators. Decompression with or without Fusion in Degenerative Lumbar Spondylolisthesis. N Engl J Med. 2021 Aug 5;385(6):526-538. doi: 10.1056/NEJMoa2100990.

    PubMed 34347953

Questions about this trial

What is this clinical trial studying?

An observational study of Degenerative Lumbar Spondylolisthesis, run by University Hospital of North Norway at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Eirik Mikkelsen, MD (eirik.mikkelsen@unn.no), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Estimated reoperations rate (n, %) at 10 years follow-up (Survival function (S(t), t=10 years) for first reoperation) by treatment group (time frame: From date of index operation (2007-2015) until end of follow up August 31st 2023). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06407063, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in